

## Supplementary material for

### **L-Enantiomers of Transition State Analogue Inhibitors Bound to Human Purine Nucleoside Phosphorylase**

Agnes Rinaldo-Matthis,<sup>‡</sup> Andrew S. Murkin,<sup>‡</sup> Udipi A. Ramagopal,<sup>‡</sup> Keith Clinch,<sup>§</sup> Simon P. H. Mee,<sup>§</sup> Gary B. Evans,<sup>§</sup> Peter C. Tyler,<sup>§</sup> Richard H. Furneaux,<sup>§</sup> Steven C. Almo,<sup>‡</sup> and Vern L. Schramm<sup>‡,\*</sup>

<sup>‡</sup>*Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461 and* <sup>§</sup>*Carbohydrate Chemistry Team, Industrial Research Ltd., Lower Hutt, New Zealand.*

### **Materials and Methods**

*Determination of inhibition constants.* Kinetic studies of the interactions between L-ImmH and L-DADMe-ImmH and human PNP were carried out by the methods previously reported.<sup>1</sup> Inhibitor and inosine concentrations were determined spectrophotometrically using  $\epsilon_{261} = 9.54 \text{ mM}^{-1} \text{ cm}^{-1}$  and  $\epsilon_{260} = 7.1 \text{ mM}^{-1} \text{ cm}^{-1}$ , respectively.<sup>2,3</sup> Inhibition constants were determined from nonlinear fitting to the

$$v_i = \frac{v_o[S]}{[S] + K_m \left(1 + \frac{[I]}{K_i}\right)}$$

equation for competitive inhibition,

where  $v_i$  and  $v_o$  are initial (for  $K_i$ ) or final (for  $K_i^*$ ) steady-state rates in the presence and absence of inhibitor, respectively, and  $K_m = 40 \text{ }\mu\text{M}$  for inosine.<sup>4</sup>

*Crystallization of human PNP in complex with L-ImmH and L-DADMe-ImmH.* The protein was expressed and purified using the same procedure as described before.<sup>5</sup> The purified protein (conc. ~30 mg/mL) was mixed with 1 mM inhibitor and 1 mM  $\text{KH}_2\text{PO}_4$  before crystallization trials. The human PNP•L-ImmH• $\text{PO}_4$  complex was crystallized using sitting drops that were equilibrated by vapor diffusion at 18 °C against an 80- $\mu\text{L}$  reservoir containing 1.8 M ammonium dihydrogen phosphate and 100 mM sodium citrate, pH 5.0, where 1  $\mu\text{L}$  of the protein solution was mixed with 1  $\mu\text{L}$  of the reservoir solution. The PNP•L-DADMe-ImmH• $\text{PO}_4$  complex was crystallized in a similar manner against a 1-mL reservoir containing 2.3 M ammonium dihydrogen phosphate and 100 mM sodium citrate, pH 5.0, where 3  $\mu\text{L}$  of the protein solution was mixed with 3  $\mu\text{L}$  of the reservoir solution.

*Data collection.* Crystals were soaked in mother liquor supplemented with 20% glycerol and flash cooled to  $-178 \text{ }^\circ\text{C}$  prior to data collection. Diffraction is consistent

with the space group H32 with one molecule in the asymmetric unit. The Matthews coefficient was  $4.8 \text{ \AA}^3/\text{Da}$ , which corresponds to a solvent content of 76%. Diffraction data were collected to a resolution of  $2.9 \text{ \AA}$  for the L-ImmH complex and  $2.1 \text{ \AA}$  for the L-DADMe-ImmH complex at beamline X29A at the National Synchrotron Light Source, Brookhaven National Laboratory using an ADSC Quantum 315 detector. The HKL2000 suite<sup>6</sup> was used for integration and scaling of the data (see Table 2 in main text).

*Structure determination and refinement.* The complex structures were solved by molecular replacement using the human PNP structure 1RR6.pdb as a template. Molecular replacement with MOLREP<sup>7</sup> and refinement with REFMAC5<sup>8</sup> were carried out using the CCP4i package.<sup>9</sup> COOT<sup>10</sup> was used for molecular modeling, and figures were generated using PyMOL.<sup>11</sup>

## References

1. Miles, R. W.; Tyler, P. C.; Furneaux, R. H.; Bagdassarian, C. K.; Schramm, V. L. *Biochemistry* **1998**, *37*, 8615-8621.
2. Lim, M.-I.; Ren, Y.-Y.; Otter, B. A.; Klein, R. S. *J. Org. Chem.* **1983**, *48*, 780-788.
3. Dawson, R. M. C.; Elliott, D. C.; Elliott, W. H.; Jones, K. M. *Data for Biochemical Research*, 3rd ed., **1986**, Clarendon Press, Oxford, U.K.
4. Erion, M. D.; Takabayashi, K.; Smith, H. B.; Kessi, J.; Wagner, S.; Honger, S.; Shames, S. L.; Ealick, S. E. *Biochemistry* **1997**, *36*, 11725-11734.
5. Murkin, A. S.; Birck, M. R.; Rinaldo-Matthis, A.; Shi, W.; Taylor, E. A.; Almo, S. C.; Schramm, V. L. *Biochemistry* **2007**, *46*, 5038-5049.
6. Otwinowski, Z.; Minor, W. *Methods Enzymol.* **1997**, *276*, 307-326.
7. Vagin, A., Teplyakov, A. *J. Appl. Cryst.* **1997**, *30*, 1022-1025.
8. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. *Acta Crystallogr. D.* **1997**, *53*, 240-255.
9. Potterton, E.; Briggs, P.; Turkenburg, M.; Dodson, E. *Acta Crystallogr. D.* **2003**, *59*, 1131-1137.
10. Emsley, P.; Cowtan, K. *Acta Crystallogr. D.* **2004**, *60*, 2126-2132.
11. DeLano, W. L. *Curr. Opin. Struct. Biol.* **2002**, *12*, 14-20.